Good Life Advisors LLC Cuts Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Good Life Advisors LLC cut its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 20.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 304 shares of the biopharmaceutical company’s stock after selling 80 shares during the quarter. Good Life Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $217,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in the stock. Financial Perspectives Inc raised its position in Regeneron Pharmaceuticals by 10.9% in the fourth quarter. Financial Perspectives Inc now owns 193 shares of the biopharmaceutical company’s stock valued at $137,000 after purchasing an additional 19 shares during the period. Alberta Investment Management Corp purchased a new position in Regeneron Pharmaceuticals in the fourth quarter valued at about $5,058,000. Klingman & Associates LLC increased its position in shares of Regeneron Pharmaceuticals by 13.2% during the fourth quarter. Klingman & Associates LLC now owns 291 shares of the biopharmaceutical company’s stock worth $207,000 after acquiring an additional 34 shares during the last quarter. Callahan Advisors LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth about $617,000. Finally, Cardinal Capital Management increased its position in shares of Regeneron Pharmaceuticals by 0.5% during the fourth quarter. Cardinal Capital Management now owns 7,871 shares of the biopharmaceutical company’s stock worth $5,607,000 after acquiring an additional 36 shares during the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Up 0.6 %

NASDAQ:REGN opened at $700.33 on Friday. The stock has a 50 day moving average of $699.40 and a 200-day moving average of $883.75. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $76.56 billion, a PE ratio of 18.29, a price-to-earnings-growth ratio of 2.30 and a beta of 0.08. Regeneron Pharmaceuticals, Inc. has a 52 week low of $642.00 and a 52 week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. The firm had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm’s quarterly revenue was up 10.3% on a year-over-year basis. During the same period last year, the company posted $11.86 EPS. Analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be paid a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.50%. The ex-dividend date of this dividend is Thursday, February 20th.

Analyst Ratings Changes

A number of brokerages have recently issued reports on REGN. Bank of America reaffirmed an “underperform” rating and set a $565.00 target price on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 10th. StockNews.com lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 4th. Canaccord Genuity Group began coverage on Regeneron Pharmaceuticals in a research report on Tuesday, December 17th. They set a “hold” rating and a $165.00 target price on the stock. TD Cowen dropped their target price on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating on the stock in a research report on Tuesday, February 4th. Finally, UBS Group lowered Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $1,130.00 to $738.00 in a research report on Thursday, January 16th. One analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $973.13.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.